Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio, Novartis International AG

Release Date: 2010-01-26

Novartis completes CEO succession process with appointment of Joe Jimenez as new CEO and simplified leadership organization

Group delivers sustained business expansion and profit improvement with all divisions contributing to strong performance in 2009.

Net sales rise 11% in local currencies (lc) to USD 44.3 billion (+7% in USD), as innovative products drive Pharmaceuticals to industry-leading growth and Vaccines and Diagnostics sells over 100 million influenza A (H1N1) pandemic vaccine doses.

Core operating income grows 11% to USD 11.4 billion, as margin improves to 25.8% of net sales on business expansion and productivity gains. Core net income rises 8% to USD 10.3 billion, at a lower pace than core operating income mainly due to Alcon-related financing costs. Free cash flow before dividends advances 24% to USD 9.4 billion.

More than 30 drug approvals and full pipeline with 145 projects in pharmaceutical clinical development, of which 60 involve new molecular entities. Forward productivity program exceeds savings goal by nearly 50% and a year ahead of schedule.

Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales. New management in place for the next phase of growth.

Type:	NORMAL
Company:	Novartis International AG
Country:	Switzerland